BVS vs. LYRA, GUTS, CERS, TCMD, LUNG, CVRX, SGHT, SRDX, NPCE, and TLSI
Should you be buying Bioventus stock or one of its competitors? The main competitors of Bioventus include Lyra Therapeutics (LYRA), Fractyl Health (GUTS), Cerus (CERS), Tactile Systems Technology (TCMD), Pulmonx (LUNG), CVRx (CVRX), Sight Sciences (SGHT), Surmodics (SRDX), NeuroPace (NPCE), and TriSalus Life Sciences (TLSI). These companies are all part of the "surgical & medical instruments" industry.
Bioventus (NYSE:BVS) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, community ranking, profitability, valuation, institutional ownership and risk.
Bioventus received 3 more outperform votes than Lyra Therapeutics when rated by MarketBeat users. However, 70.97% of users gave Lyra Therapeutics an outperform vote while only 59.52% of users gave Bioventus an outperform vote.
62.9% of Bioventus shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 29.1% of Bioventus shares are held by insiders. Comparatively, 17.4% of Lyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Bioventus has a net margin of -30.49% compared to Lyra Therapeutics' net margin of -4,099.82%. Bioventus' return on equity of 2.25% beat Lyra Therapeutics' return on equity.
Bioventus has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500.
Bioventus currently has a consensus price target of $7.67, suggesting a potential upside of 93.12%. Lyra Therapeutics has a consensus price target of $12.67, suggesting a potential upside of 188.53%. Given Lyra Therapeutics' higher probable upside, analysts plainly believe Lyra Therapeutics is more favorable than Bioventus.
In the previous week, Lyra Therapeutics had 12 more articles in the media than Bioventus. MarketBeat recorded 14 mentions for Lyra Therapeutics and 2 mentions for Bioventus. Bioventus' average media sentiment score of 0.00 beat Lyra Therapeutics' score of -0.25 indicating that Bioventus is being referred to more favorably in the media.
Lyra Therapeutics has lower revenue, but higher earnings than Bioventus. Lyra Therapeutics is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.
Summary
Bioventus beats Lyra Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Bioventus News Delivered to You Automatically
Sign up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bioventus Competitors List
Related Companies and Tools
